Literature DB >> 6232458

Reduced Langerhans' cell Ia antigen and ATPase activity in patients with the acquired immunodeficiency syndrome.

D V Belsito, M R Sanchez, R L Baer, F Valentine, G J Thorbecke.   

Abstract

We investigated the possible role of a defect in antigen-presenting cells in the acquired immunodeficiency syndrome (AIDS), by enumeration of Langerhans' cells, the epidermal antigen-presenting cells. These cells were stained for the characteristic markers, surface Ia antigen and surface ATPase activity. A significant reduction was observed in the number of stained cells per square millimeter of body-surface area in 24 patients with AIDS and either opportunistic infections (Ia, 258 +/- 34, and ATPase, 274 +/- 46) or Kaposi's sarcoma (Ia, 378 +/- 100, and ATPase, 530 +/- 26), as compared with 38 appropriate controls (Ia, 721 +/- 13, and ATPase, 693 +/- 12). Examination of six patients with an "AIDS-related complex" revealed significantly reduced numbers of Langerhans' cells per square millimeter; this reduction was more pronounced in staining for Ia antigen (306 +/- 69) than in staining for ATPase activity (517 +/- 101). Given the known role of Ia expression in antigen presentation, we suggest that functional alterations in Langerhans' cells, and perhaps also in antigen-presenting cells in tissues other than skin, may be involved in the pathogenesis of AIDS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232458     DOI: 10.1056/NEJM198405173102002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  44 in total

Review 1.  Antibody responses in HIV infection.

Authors:  A J Pinching
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

2.  Increase in dendritic cell numbers, their function and the proportion uninfected during AZT therapy.

Authors:  M Gompels; S Patterson; M S Roberts; S E Macatonia; A J Pinching; S C Knight
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 3.  Crusted scabies in a patient with the acquired immunodeficiency syndrome.

Authors:  J Jessurun; J Romo-Garcia; O Lopez-Denis; J E Olvera-Rabiela
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

4.  Recombinant human gamma interferon enhances in vitro activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome.

Authors:  W Heagy; T B Strom; V E Kelley; J Collela; C Crumpacker; J M Williams; H M Shapiro; L Laubenstein; R Finberg
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

5.  Impaired monocyte-to-macrophage maturation in patients with lymphadenopathy syndrome.

Authors:  J Offenberger; T Lieu; O Frick; A J Ammann
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

6.  Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis.

Authors:  G Poli; B Bottazzi; R Acero; L Bersani; V Rossi; M Introna; A Lazzarin; M Galli; A Mantovani
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

Review 7.  Role of epidermal Langerhans cells in viral infections.

Authors:  E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

9.  The immunohistology of non-T cells in the acquired immunodeficiency syndrome.

Authors:  G S Wood; B F Burns; R F Dorfman; R A Warnke
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

10.  Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma.

Authors:  W Heagy; V E Kelley; T B Strom; K Mayer; H M Shapiro; R Mandel; R Finberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.